Novavax 3Q Loss Widens on Research Costs
14th Nov 2006, 16:19 GMT
Biopharmaceutical company Novavax said its Q3 loss widened on higher costs for developing its flu vaccine program.
Novavax 3Q Loss Widens on Research Costs related news:
- Favrille 3Q Loss Widens on Costs — StratWire - Business of Healthcare NewsFeed
- Iomai 3Q Loss Widens — StratWire - Business of Healthcare NewsFeed
- Repros Therapeutics 3Q Loss Widens — Financial News News from StratCenter.com
- GMH 3Q loss widens, no guidance offered — bizjournals.com Banking & Financial Services:Investing headlines
- UGS Corp. posts wider 3Q loss — Latest news from Dallas Business Journal
- PFSweb loss widens — bizjournals.com High Tech:E-Commerce headlines
- Corautus Genetics chips at Q3 loss — bizjournals.com Health Care:Pharmaceuticals headlines
- US LEC loss widens in third quarter — Latest news from Charlotte Business Journal
- Revenues decline, loss widens for Spheris Inc. — Latest news from Nashville Business Journal
- PokerTek posts 3Q loss of $2.3M — Latest news from Charlotte Business Journal
Latest news from Operations-Related News from StratCenter.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies